Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiangiogenic therapy.

Daniel Albo1, Thomas N Wang, George P Tuszynski

  • 1Department of Surgery, Section of Surgical Oncology, Medical College of Georgia, Augusta, GA 30912, USA.

Current Pharmaceutical Design
|February 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When physician supply does not meet patient demand: A looming epidemic in vascular and renal care for a community with the highest incidence of end-stage renal disease in the United States.

American journal of surgery·2024
Same author

From the borders edge to the brink of death: A case of a traumatic pancreatic injury and Whipple procedure in the Rio Grande Valley.

Trauma case reports·2023
Same author

Physician-Targeted Interventions Reduce Surgical Expense and Improve Value-Driven Health Outcomes.

The Journal of surgical research·2023
Same author

Adjusting Drain Fluid Amylase for Drain Volume Does Not Improve Pancreatic Fistula Prediction.

The Journal of surgical research·2023
Same author

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2022
Same author

External validation of four Pancreatic Fistula Risk Score models in the Deep South US: Do racial disparities affect pancreatic fistula prediction?

American journal of surgery·2022
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
Same journal

Corrigendum to: miRNA in Diagnosis and Therapeutics of Tuberculosis: Importance in Latent and Brain Associated Pathologies.

Current pharmaceutical design·2026
See all related articles

Antiangiogenic agents target tumor blood vessel formation, offering a novel cancer treatment. While promising due to fewer side effects and broader applicability, clinical trial challenges remain.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis.
  • The "angiogenic switch" enables tumor cells to invade surrounding tissues and spread.
  • Antiangiogenic agents represent a targeted approach to cancer therapy.

Purpose of the Study:

  • To review current antiangiogenic agents and their role in cancer treatment.
  • To discuss the advantages of antiangiogenic therapy over traditional chemotherapy.
  • To explore challenges and future directions in clinical antiangiogenic drug development.

Main Methods:

  • Review of scientific literature on angiogenesis and antiangiogenic agents.
  • Analysis of theoretical benefits and potential toxicities of antiangiogenic drugs.

Related Experiment Videos

  • Examination of ongoing clinical trials and their implications.

    • Main Results:

    • Antiangiogenic agents target tumor endothelial cells, potentially bypassing resistance mechanisms.
    • These agents may offer reduced toxicity compared to standard chemotherapy, avoiding cytopenias.
    • Potential for broad applicability across various tumor types, independent of cell characteristics.

    Conclusions:

    • Antiangiogenic therapy holds significant promise for cancer treatment and prevention.
    • Overcoming obstacles in clinical trials is crucial for accurately assessing efficacy.
    • Further research and development are needed to fully realize the potential of antiangiogenic drugs.